Change in serum lipids after acute coronary syndromes: secondary analysis of SPACE ROCKET study data and a

Julian H Barth1, Beryl M Jackson, Amanda J Farrin

  • 1Clinical Biochemistry, Leeds General Infirmary, Leeds, United Kingdom. julian.barth@leedsth.nhs.uk

Clinical Chemistry
|August 24, 2010
PubMed

Insights

Serum cholesterol significantly drops after myocardial infarction (MI). New research shows a 10% decrease in total cholesterol post-MI, highlighting the clinical importance of early lipid level measurement.

Area of Science:

  • Cardiology
  • Clinical Lipidology

Background:

  • Traditional belief: serum cholesterol falls significantly post-myocardial infarction (MI), returning to baseline in ~3 months.
  • Recent challenges question the magnitude and clinical significance of this post-MI cholesterol drop.

Purpose of the Study:

  • To re-evaluate the extent and clinical relevance of serum lipid changes immediately following acute myocardial infarction (AMI).
  • To determine the optimal timing for serum lipid measurement in AMI patients.

Main Methods:

  • Analysis of serum lipids from participants in the SPACE ROCKET trial (day 1 vs. days 2-4 post-AMI).
  • Comprehensive literature review and meta-analysis of 25 studies reporting absolute lipid changes post-AMI.

Main Results:

  • SPACE ROCKET trial: Mean total cholesterol decreased by 0.71 mmol/L (P < 0.0001) between day 1 and days 2-4 post-AMI.
  • Meta-analysis: A 9-11% fall in total cholesterol observed 3-14 days post-AMI.
  • Meta-analysis: Triglycerides showed an 18% rise from baseline between day 9 and 12 weeks post-AMI.

Conclusions:

  • A significant 10% decrease in total cholesterol occurs after AMI, carrying substantial clinical significance.
  • Serum lipid measurements in AMI patients are most informative when taken within the initial hours of presentation.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...